Research To Practice | Oncology Videos

Featuring slide presentations and related discussion from Drs Andrew Evens, Ian Flinn and Gilles Salles, including the following topics: Follicular Lymphoma — Andrew Evens, DO, MSc (0:00) Mantle Cell Lymphoma — Ian Flinn, MD, PhD (36:39) Diffuse Large B-Cell Lymphoma — Gilles Salles, MD, PhD (1:03:37) CME information and select publications

Featuring perspectives from Dr Erika Hamilton, including the following topics: Introduction (0:00) Case: A woman in her early 50s with metastatic HER2-positive breast cancer — Nick Leasure, MD (19:02) Case: A woman in her mid-50s with metastatic ER/PR-negative, HER2-positive breast cancer — Estelamari Rodriguez, MD, MPH (22:08) Cases: Three patients with metastatic HER2-positive disease — Kapisthalam (KS) Kumar, MD (24:43) Case: A woman in her early 40s with localized ER/PR-negative, HER2-positive breast cancer — Dr Leasure (31:55) Case: A woman in her late 30s with localized triple-positive breast cancer — Ruth O'Regan, MD (36:34) Case: A woman in her late 40s with localized ER/PR-positive, HER2-positive breast cancer and residual disease — Dr Leasure (40:17) Case: A woman in her early 60s with high-risk, localized ER-positive, HER2-positive breast cancer — Debra Patt, MD, PhD, MBA (44:08) Journal Club with Dr Hamilton (46:00) Beyond the Guidelines (54:06) CME information and select publications

Featuring perspectives from Dr Virginia Kaklamani, including the following topics: Introduction: Adjuvant Therapy for Breast Cancer — NIH Consensus Statement 2000 (0:00) Case: A premenopausal woman in her early 30s with high-risk localized ER-positive breast cancer — Susmitha Apuri, MD (15:06) Case: A premenopausal woman in her late 40s with localized ER-positive, node-positive breast cancer — Recurrence Score® 14 — Reshma Mahtani, DO (20:22) Case: A premenopausal woman in her mid-40s with localized ER-positive breast cancer — Ruth O'Regan, MD (22:28) Case: A woman in her mid-80s with ER-positive metastatic breast cancer (mBC) — Vikas Malhotra, MD (28:51) Case: A woman in her late 60s with ER-positive mBC — PIK3CA mutation, microsatellite stable, tumor mutation burden 20 mut/Mb — Mamta Choksi, MD (37:36) ESMO 2021 Review (43:20) Case: A woman in her late 50s with ER-positive mBC — PD-L1-negative — Debra Patt, MD, PhD, MBA (50:50) Beyond the Guidelines (53:52) CME information and select publications

Featuring perspectives from Drs Arjun Balar, Ashish Kamat, Guru Sonpavde and Robert Svatek, including the following topics: Personalized Continuing Medical Education Introduction (0:00) Understanding the Millennial Physician — Jason Hafron, MD (2:30) Non-Muscle-Invasive Urothelial Bladder Cancer (UBC) Case: A man in his late 70s with bacillus Calmette-Guérin (BCG)-refractory non-muscle-invasive bladder cancer — David S Morris, MD (9:27) Case: A man in his mid-60s with high-risk non-muscle-invasive UBC — Gordon A Brown, DO (14:45) Case: A man in his late 50s with high-risk, BCG-refractory non-muscle-invasive bladder cancer — Dr Hafron (23:03) Case: A man in his mid-80s with recurrent high-grade noninvasive papillary carcinoma — Dr Morris (32:16) Neoadjuvant and Adjuvant Treatment of Muscle-Invasive UBC Case: A man in his mid-80s with muscle-invasive bladder cancer who declines cystectomy — Sulfi Ibrahim, MD (37:22) Selection of Patients for Neoadjuvant Therapy — Dr Morris (44:08) Case: A man in his late 70s with Gleason 4 + 3 adenocarcinoma of the prostate and urothelial carcinoma — Dr Hafron (53:03) Treatment of Metastatic UBC Urologists' Questions about Second- and Later-Line Therapies and Management of Side Effects — Dr Morris (1:02:11) Case: A woman in her early 70s with metastatic UBC, PD-L1 30% — Dr Ibrahim (1:09:15) Case: A woman in her mid-50s with muscle-invasive bladder cancer — Dr Brown (1:25:20) CME information and select publications

Featuring slide presentations and related discussion from Drs Arjun Balar, Ashish Kamat, Guru Sonpavde and Robert Svatek, including the following topics: Current and Future Role of Novel Therapies in the Management of Metastatic Urothelial Cancer — Arjun Balar, MD (0:00) Immuno-oncology and Novel Agents in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer — Ashish M Kamat, MD, MBBS (28:11) Optimal Application of Immune Checkpoint Inhibitors in Metastatic Urothelial Bladder Cancer — Guru Sonpavde, MD (57:20) Current and Potential Future Role of Immune Checkpoint Inhibitors as Adjuvant and Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer — Robert Svatek, MD (1:33:20) CME information and select publications

Featuring perspectives from Dr Stephen Ansell and Ms Robin Klebig, including the following topics: Diffuse Large B-Cell Lymphoma (DLBCL) Introduction (0:00) Key Recent FDA Approvals for DLBCL (1:30) Case: A woman in her early 80s with relapsed DLBCL (21:07) Hodgkin Lymphoma Novel Agents and Combination Therapies for the Management of Hodgkin Lymphoma (22:48) Case: A man in his late 70s with newly diagnosed Hodgkin lymphoma (30:54) Follicular Lymphoma Key Recent Pivotal Data Sets/FDA Approvals for Follicular Lymphoma (36:01) Case: A man in his mid-70s with newly diagnosed follicular lymphoma (39:23) Mantle Cell Lymphoma Key Recent Developments in Mantle Cell Lymphoma (44:45) Case: A woman in her early 60s with relapsed/refractory mantle cell lymphoma (54:23) NCPD information and select publications

Featuring slide presentations and related discussion from Drs Courtney DiNardo, Daniel Pollyea, David Sallman and Eunice Wang, including the following topics: Treatment Options for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) without Targetable Mutations — Daniel A Pollyea, MD, MS (0:00) Optimal Management of AML with Targetable Mutations — Courtney D DiNardo, MD, MSCE (28:03) Other Currently Available and Investigation Treatment Strategies for AML — Eunice S Wang, MD (49:37) Current and Future Therapeutic Approaches for Patients with Myelodysplastic Syndromes (MDS) — David Sallman, MD (1:28:55) CME information and select publications  

Featuring case presentations from Drs Courtney DiNardo, Daniel Pollyea, David Sallman and Eunice Wang, including the following topics: Case: A woman in her mid-80s with newly diagnosed acute myeloid leukemia (AML) — Daniel A Pollyea, MD, MS (0:00) Case: A man in his early 70s with AML and a complex monosomal karyotype — Dr Pollyea (4:02) Case: A woman in her mid-70s with newly diagnosed AML with trisomy 21 and AXLS1 and RUNX1 mutations — Dr Pollyea (5:22) Case: A woman in her late 70s with AML and a FLT3-ITD mutation — Courtney D DiNardo, MD, MSCE (7:41) Case: A man in his late 70s with AML and diploid cytogenetics — Dr DiNardo (11:46) Case: A man in his mid-60s with secondary AML and DNMT3A and FLT3-ITD mutations — Eunice S Wang, MD (17:33) Case: A woman in her late 60s with lower-risk myelodysplastic syndrome (MDS) — David Sallman, MD (25:55) Case: A man in his late 70s with high-risk MDS — Dr Sallman (29:26) CME information and select publications

Featuring perspectives from Dr Jeremy Abramson and Ms Elizabeth Zerante, including the following topics:  Introduction (0:00) Toxicities with Chimeric Antigen Receptor (CAR) T-Cell Therapy — Grading, Management and Patient Education (10:56) Case: A woman in her early 60s with relapsed/refractory chronic lymphocytic leukemia (CLL) (36:28) Case: A woman in her early 60s with relapsed/refractory CLL/SLL (small lymphocytic lymphoma) (40:46) Case: A man in his early 80s with a history of CLL and double-hit diffuse large B-cell lymphoma (45:15) Clinical Use of CAR T-Cell Therapies for CLL and Lymphomas (55:25) CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia and myelodysplastic syndromes. Featuring perspectives from Drs Mark Levis and David Sallman, including the following topics: Introduction Challenge of New Treatment Options for AML; Role of CPX-351 — Dr Peles Hypomethylating Agents/Venetoclax: Appropriate Candidates, Tolerability and Dose Adjustments — Dr Kumar Personal Experience with Administering Azacitidine/Venetoclax — Dr Choksi Approach to Treatment-Associated Adverse Events After the First Cycle of Venetoclax/HMA in Patients with AML Chalk Talk — Dr Sallman (Part 1) Case: A woman in her late 60s with AML — Dr Gandhi Appropriate Use of Antifungal Agents for Patients Receiving Venetoclax — Dr Apuri Role of FLT3 and IDH1/2 Inhibitors for Patients Who Are Ineligible for Intensive Induction Therapy — Dr Peles Up-Front Management of AML in Older Patients with an IDH Mutation Who Are Not Eligible for Intensive Therapy Chalk Talk — Dr Sallman (Part 2) Management of Secondary AML in Younger Patients Chalk Talk — Dr Levis (Part 1) Case: A woman in her early 80s initially treated for idiopathic thrombocytopenic purpura — Ferdy Santiago, MD Case: A woman in her late 80s with low-grade myelodysplastic syndromes with ringed sideroblasts — Dr Apuri Luspatercept for Patients with Lower-Risk Myelodysplastic Syndromes Chalk Talk — Dr Levis (Part 2) CME information and select publications  

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in multiple myeloma. Featuring perspectives from Drs Noopur Raje and Saad Zafar Usmani, including the following topics: Introduction Front-Line Treatment for Transplant-Ineligible Patients; Incorporation of CAR T-Cell Therapy — Dr Choksi Up-Front Management of Multiple Myeloma in Young Patients with Adverse Cytogenetics Chalk Talk — Dr Raje Efficacy and Tolerability of Subcutaneous versus IV Daratumumab in Patients with Multiple Myeloma Chalk Talk — Dr Usmani (Part 1) Substitution of Isatuximab for Daratumumab; Role of Transplant; Role of Minimal Residual Disease — Dr Kumar Nonresearch Role of Venetoclax for Patients with R/R Multiple Myeloma and t(11;14) or Bcl-2 Overexpression Chalk Talk — Dr Usmani (Part 2) Case: A man in his mid-60s with relapsed/refractory multiple myeloma with t(4:14) and del(17p) — Dr Usmani Comment on Dr Usmani's 64-Year-Old Man: High-Risk Cytogenetics — Paul G Richardson, MD and Peter Voorhees, MD Comment on Dr Usmani's 64-Year-Old Man: CAR T-Cell Therapy — Drs Richardson and Voorhees CAR T-Cell Therapy Investigational Strategies Chalk Talk — Dr Raje Investigational Bispecific Antibodies for R/R Multiple Myeloma Chalk Talk — Dr Usmani CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in chronic lymphocytic leukemia and lymphomas. Featuring perspectives from Drs Brad Kahl and Andrew Zelenetz, including the following topics: Introduction Case: A man in his early 70s with relapsed mantle cell lymphoma — Zanetta S Lamar, MD Chimeric Antigen-Receptor (CAR) T-Cell Therapy and Use in Elderly Patients — Dr Gandhi Optimal Second-Line Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) After R-CHOP Chalk Talk — Dr Zelenetz Sequencing Tafasitamab/Lenalidomide with Other Novel Agents for Relapsed/Refractory (R/R) DLBCL Chalk Talk — Dr Kahl Case: A woman in her early 20s with mixed cellularity classical Hodgkin lymphoma — Dr Peles Hodgkin Lymphoma Chalk Talk — Dr Kahl Treatment of p53-Negative versus p53-Positive Disease — Dr Kumar Selection of Front-Line BTK Inhibitors for Patients with Chronic Lymphocytic Leukemia Chalk Talk — Dr Zelenetz Combining Venetoclax with an Anti-CD20 Antibody for Relapsed Chronic Lymphocytic Leukemia Chalk Talk — Dr Kahl Case: A man in his early 80s with Grade I-II follicular lymphoma — Dr Shameem Treatment Options for Relapsed Follicular Lymphoma — Dr Peles Role of Tazemetostat in Therapy for Relapsed Follicular Lymphoma with and without an EZH2 Mutation Chalk Talk — Dr Zelenetz CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in genitourinary cancers. Featuring perspectives from Drs Neeraj Agarwal and Daniel Petrylak, including the following topics: Introduction Case: A woman in her early 50s with metastatic renal cell carcinoma with rhabdoid features — Dr Kumar Comparing First-Line Treatment Options for Metastatic Renal Cell Carcinoma Chalk Talk — Dr Petrylak Second-Line Treatment of Metastatic Renal Cell Carcinoma After Progression on Checkpoint Inhibitor-Based Therapy Chalk Talk — Dr Agarwal Case: A healthy man in his late 80s with locally recurrent castration-resistant prostate cancer (CRPC) — Dr Guancial Case: A man in his mid-80s with metastatic CRPC and a somatic BRCA2 mutation — Dr Zafar 177Lu-PSMA-617 in Metastatic CRPC Chalk Talk — Dr Agarwal Case: A man in his early 60s with metastatic CRPC and an ATM mutation — Dr Shameem Genomic Testing and PARP Inhibition for Metastatic Prostate Cancers with a BRCA Mutation Chalk Talk — Dr Petrylak Case: A woman in her late 70s with non-muscle-invasive urothelial bladder cancer — Dr Gandhi Case: A man in his late 60s with localized urothelial bladder carcinoma (UBC) — Dr Choksi Case: A woman in her early 70s with high-TMB muscle-invasive UBC and high-PD-L1 expression — Dr Guancial Genomic Testing and PARP Inhibition for Metastatic Prostate Cancers with a BRCA Mutation Chalk Talk — Dr Petrylak Sequencing Enfortumab Vedotin and Other Targeted Therapies for Metastatic UBC Chalk Talk — Dr Agarwal CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in gastrointestinal cancers. Featuring perspectives from Drs Tanios Bekaii-Saab and Kristen Ciombor, including the following topics: Introduction Case: A woman in her early 70s with metastatic hepatocellular carcinoma (HCC) — Dr Peles Treatment Options for Child-Pugh B HCC — Dr Choksi First-Line Treatment for Advanced HCC with Child-Pugh B or C Cirrhosis — Dr Bekaii-Saab Second-Line Systemic Treatment for Advanced HCC After Atezolizumab/Bevacizumab — Dr Ciombor Case: A woman in her early 60s with microsatellite instability-high Stage IV colorectal cancer (CRC) and a BRAF V600E mutation — Ina J Patel, DO Case: A woman in her late 50s with microsatellite stable metastatic CRC and a KRAS G12C mutation — Dr Apuri First-Line Immunotherapy for MSI-High dMMR Metastatic CRC Chalk Talk — Dr Ciombor ctDNA in Early and Metastatic CRC Chalk Talk — Dr Bekaii-Saab Gastric, Gastroesophageal and Esophageal Cancers Chalk Talk — Dr Ciombor Case: A woman in her late 60s with metastatic pancreatic cancer — Lowell L Hart, MD Case: A woman in her early 90s with metastatic cholangiocarcinoma — Dr Choksi CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in lung cancer. Featuring perspectives from Drs Lecia Sequist and David Spigel, including the following topics: Introduction Case: A woman in her early 70s with microsatellite stable metastatic adenocarcinoma of the lung and a HER2 mutation, PD-L1 TPS 0% — Dr Zafar Case: A man in his mid-80s with localized adenocarcinoma of the lung and an EGFR exon 19 deletion — Dr Gandhi Case: A woman in her late 70s with metastatic adenocarcinoma of the lung, somatic BRCA2 and KRAS G12C mutations and high tumor mutation burden (TMB) — Kapisthalam (KS) Kumar, MD Targeted Therapy for Lung Cancer Chalk Talk — Dr Spigel Case: A man in his mid-60s with Stage IIIA (8-cm, node-negative) adenocarcinoma of the lung — Shachar Peles, MD Case: A man in his mid-50s with Stage IIIA adenocarcinoma of the lung — Dr Choksi Case: A woman in her mid-60s with metastatic adenocarcinoma of the lung, PD-L1 56% — Dr Gandhi First-Line Treatment of PD-L1-Negative Metastatic NSCLC without a Targetable Mutation Chalk Talk — Dr Sequist Selecting Patients with Localized NSCLC for Adjuvant Immunotherapy Chalk Talk — Dr Spigel Case: A man in his early 50s with extensive-stage small cell lung cancer (SCLC) — Dr Apuri Case: A man in his mid-60s with extensive-stage SCLC and concurrent prostate cancer — Dr Gandhi CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in breast cancer. Featuring perspectives from Drs Ann Partridge and Mark Pegram, including the following topics: Introduction Case: A woman in her late 40s with ER/PR-negative, HER2-positive metastatic breast cancer (mBC) — Syed F Zafar, MD Clinical Implications of the DESTINY-Breast03 Trial — Elizabeth Guancial, MD Case: A woman in her mid-70s with ER-positive, PR-negative, HER2-positive mBC with bone and brain metastases — Sunil Gandhi, MD DESTINY-Breast03 Trial Chalk Talk — Dr Pegram Postneoadjuvant/Adjuvant Neratinib for HER2-Positive Breast Cancer Chalk Talk — Dr Partridge Case: A woman in her early 50s with ER/PR-positive, HER2-negative mBC — Susmitha Apuri, MD Case: A premenopausal woman in her early 50s with ER/PR-positive, node-positive x 1 breast cancer — Raji Shameem, MD Case: A woman in her early 60s with ER/PR-positive breast cancer — Dr Apuri Genomic Assays in ER-Positive Breast Cancer Chalk Talk — Dr Pegram Selecting a First-Line CDK4/6 Inhibitor for ER-Positive Metastatic Breast Cancer Chalk Talk — Dr Partridge Case: A woman in her early 60s with asynchronous second primary triple-negative breast cancer (TNBC) — Mamta Choksi, MD KEYNOTE-522 Trial Chalk Talk — Dr Pegram OlympiA Trial Chalk Talk — Dr Partridge CME information and select publications

Featuring an interview with Professor Dr Arnon Kater, including the following topics: Novel agents and their use in combination therapies for chronic lymphocytic leukemia (CLL) (0:00) Case: A man in his late 70s with complex karyotype CLL with deletion 17p and a TP53 mutation (37:27) Case: A man in his early 50s with del(13q) and IGHV-mutated CLL treated with venetoclax/ibrutinib (44:24) Case: A woman in her early 70s with del(13q), del(17p) CLL with a TP53 mutation treated with ibrutinib monotherapy (47:18) CME information and select publications

Featuring perspectives from Dr Keith Pratz, including the following topics: Introduction: AML Molecular Workup (0:00) Case: A woman in her early 70s with AML with MDS-related changes — Shachar Peles, MD (10:39) Case: A man in his late 70s with AML and an IDH1 mutation — Raji Shameem, MD (23:47) Case: A man in his early 60s with therapy-related AML — Rebecca L Olin, MD, MSCE (35:20) Case: A woman in her early 70s with AML and FLT3-ITD and WT1 mutations — John Yang, MD (44:22) Case: A man in his early 60s with relapsed AML — Dr Olin (51:02) CME information and select publications

Featuring perspectives from Dr Brad Kahl, including the following topics: Introduction (0:00) Case: A woman in her late 50s with diffuse large B-cell lymphoma and risk of CNS recurrence — Mitchell R Smith, MD, PhD (6:16) Case: A man in his early 60s with Grade I/II follicular lymphoma — Ranju Gupta, MD (27:47) Case: A man in his early 50s with classical Hodgkin lymphoma, nodular sclerosis type — Mamta Choksi, MD (35:31) Case: A woman in her 80s with mantle cell lymphoma — Zanetta S Lamar, MD (47:21) Journal Club with Dr Kahl (56:43) CME information and select publications

Featuring perspectives from Professor Peter Schmid, including the following topics: Introduction (0:00) ESMO 2021 Review (1:02) Case: A Jehovah's Witness in her early 60s with metastatic triple-negative breast cancer (TNBC) – PD-L1 >1% — Nikesh Jasani, MD (31:27) Case: A woman in her mid-50s with node-positive TNBC — Joseph Martins, MD (34:43) Case: A nurse in her late 40s with TNBC and a germline BRCA2 mutation — Ranju Gupta, MD (40:53) CME information and select publications

Featuring perspectives from Dr Anthony Mato and Ms Corinne Hoffman, including the following topics: Introduction: Treatment Adherence and CLL (0:00) Case: A woman in her mid-60s with previously untreated CLL who receives acalabrutinib (12:58) Case: A man in his mid-70s with previously untreated CLL who receives venetoclax/obinutuzumab (22:42) Case: A man in his mid-70s with previously untreated CLL who receives ibrutinib (29:58) Case: A man in his late 60s with CLL who receives acalabrutinib as second-line therapy (36:23) Future Directions in CLL (U2 Regimen, Pirtobrutinib, CAR T-Cell Therapy) (55:39) NCPD information and select publications

Featuring an interview with Dr Michael Savona, including the following topics: Evolving theory of pathobiology and treatment in myelodysplastic syndromes (0:00) Case: A man in his late 60s with a history of coronary artery disease initially referred for normocytic anemia (27:00) CME information and select publications

Featuring perspectives from Dr Zev Wainberg, including the following topics: Introduction (0:00) Case: A man in his early 60s with newly diagnosed esophageal cancer -- Henna Malik, MD (8:13) Case: A man in his mid 40s with MSS, HER2-negative gastric adenocarcinoma, PD-L1 CPS: 5 -- Michael Polintan Del Rosario, MD (15:57) Case: A woman in her early 60s with MSI-high, TMB-high colon cancer -- Farshid Dayyani, MD, PhD (19:08) Case: A woman in her early 60s with MSI-high metastatic colon cancer and a BRAF mutation -- Ina J Patel, DO (27:16) Case: A man in his early 80s with hepatocellular carcinoma -- Warren S Brenner, MD (33:39) Case: A woman in her early 60s with metastatic cholangiocarcinoma and an IDH1 mutation -- Anthony Nguyen, MD (38:31) ESMO 2021 Highlights (41:27) Journal Club with Dr Wainberg (53:24) CME information and select publications

Featuring perspectives from Dr Mary-Ellen Taplin and Ms Kathy Burns, including the following topics: Introduction (0:00) Unique psychosocial issues associated with the clinical care of patients with prostate cancer (3:23) Case: A man in his early 70s with prostate cancer and lymph node and bone metastases — Kathy D Burns, RN, MSN, AGACNP-BC, OCN  Risks and potential benefits of 177Lu-PSMA-617 (37:55) Case: A man in his early 70s with metastatic CRPC with a somatic BRCA2 mutation — Ms Burns (42:58) CME information and select publications 

Featuring perspectives from Drs Jeff Sharman, Mitchell Smith and Philip Thompson, including the following topics:  Evidence-Based Therapy for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia — Mitchell R Smith, MD, PhD (0:00) Considerations in the Selection of Treatment for Special Patient Populations; Management of Adverse Events with BTK and Bcl-2 Inhibitors — Jeff Sharman, MD (35:02) Selection and Sequencing of Treatment for Relapsed/Refractory Disease; Novel Investigational Agents and Strategies — Philip A Thompson, MB, BS (1:04:47) CME information and select publications

Featuring perspectives from Dr Sara Hurvitz, including the following topics: Introduction (0:00) Case: A woman in her early 40s with metastatic triple-negative breast cancer (TNBC) — Sulfi Ibrahim, MD (12:39) Case: A woman in her mid-40s with oligometastatic TNBC — Ann Partridge, MD, MPH (29:05) Case: A woman in her early 40s with metastatic TNBC and a BRCA2 mutation — Ruth O'Regan, MD (35:44) Beyond the Guidelines (43:36) Journal Club with Dr Hurvitz (53:28) CME information and select publications

Featuring perspectives from Dr Jonathon Cohen, including the following topics: Chimeric antigen receptor (CAR) T-cell therapy for non-Hodgkin lymphomas (0:00) Case: A woman in her mid-60s with relapsed diffuse large B-cell lymphoma (DLBCL) after R-CHOP and maintenance rituximab (27:20) Case: A man in his late 50s cured of DLBCL but with long-term toxicities related to CAR T-cell therapy (32:43) Case: A man in his early 60s with progressive mantle cell lymphoma after CAR T-cell therapy (38:36) CME information and select publications

Featuring perspectives from Dr Cristina Rodriguez, including the following topics: Case: A man in his mid-40s from Guangdong Province with nasopharyngeal carcinoma (0:00) Case: A woman in her mid-50s with secretory carcinoma with an NTRK3 ETV6 mutation (19:25) Case: A man in his mid-50s, a smoker, with recurrent metastatic laryngeal squamous cell carcinoma (33:44) CME information and select publications

Featuring perspectives from Drs Ross Camidge, Alexander Drilon and Justin Gainor, including the following topics:  Selection and Sequencing of Therapy for Patients with Non-Small Cell Lung Cancer (NSCLC) with an ALK Rearrangement Introduction (0:00) Case: A woman in her mid 30s with newly diagnosed metastatic NSCLC with an ALK mutation — Nikesh Jasani, MD (5:58) Case: A woman in her early 50s with metastatic adenocarcinoma of the lung with an ALK rearrangement — Lowell L Hart, MD (10:03) Optimal Use of Recently Approved RET Inhibitors in the Care of Patients with NSCLC with RET Alterations Case: A woman in her early 60s with metastatic adenocarcinoma of the lung, PD-L1 0%, KIF5B-RET fusion — Mohamed K Mohamed, MD, PhD (15:02) Case: A man in his early 70s with metastatic adenocarcinoma of the lung, PD-L1 65%, KIF5B-RET fusion — Joshua Bauml, MD (18:08) Current and Future Directions in the Management of NSCLC with ROS1 Rearrangement Case: A man in his late 60s with metastatic adenosquamous carcinoma of the lung, PD-L1 >95%, ROS1 rearrangement — Margaret Deutsch, MD (25:24) Case: A woman in her late 50s with metastatic adenocarcinoma of the lung with a ROS1 fusion and severe rheumatoid arthritis — Gigi Chen, MD (29:49) Rational Approaches to Targeting BRAF in Patients with NSCLC Case: A man in his early 60s with metastatic adenocarcinoma of the lung with a BRAF V600E mutation, PD-L1 TPS 80% — Neil Morganstein, MD (38:04) Case: A man in his early 70s with metastatic NSCLC with a BRAF V600E mutation — KS Kumar, MD (42:59) Other Validated Targets Beyond EGFR (eg, MET, KRAS G12C) Case: A woman in her early 70s with metastatic adenocarcinoma of the lung with MET exon 14 skipping and MET amplification mutations, PD-L1 TPS 95% — Dr Mohamed (47:02) Case: A woman in her mid 40s with metastatic adenocarcinoma of the lung with a KRAS G12C mutation — Sulfi Ibrahim, MD (50:57) CME information and select publications

Featuring a slide presentation and related discussion from Dr Daniel Lenihan. CME information and select publications

Featuring perspectives from Drs Richard Furman, Lindsey Roeker and Daniel Lenihan, including the following topics: Introduction (0:00) Chronic Lymphocytic Leukemia (CLL) (1:37) Case: A woman in her early 70s with recurrent CLL and ibrutinib-associated atrial fibrillation — Warren S Brenner, MD (3:30) Case: A woman in her mid-40s with CLL in remission on ibrutinib who experiences ventricular fibrillation — Daniel J Lenihan, MD (29:16) Case: A man in his late 70s with CLL who receives obinutuzumab/venetoclax — Dr Brenner (38:22) Mantle Cell Lymphoma (MCL) (53:25) Novel Agents and Strategies in CLL and MCL (54:46) CME information and select publications

Featuring perspectives from Drs Jamie Chaft, Solange Peters, Brendan Stiles and Eric Vallieres, including the following topics: Effect of the recent practice-changing data sets in the adjuvant and neoadjuvant treatment of non-small cell lung carcinoma (NSCLC) (0:00) Case: A woman in her late 60s with Stage IIIA squamous cell carcinoma of the lung and a high level of PD-L1 expression (7:46) Strategies to aid shared decision-making in the adjuvant setting for NSCLC (23:43) Potential role of circulating tumor DNA to detect minimal residual disease in the adjuvant and neoadjuvant settings (28:06) Choosing definitive stereotactic radiosurgery versus sublobar resection in patients with NSCLC (34:53) Case: A woman in her early 80s with PD-L1-negative, Stage IIB lung adenocarcinoma with PIK3CA and TP53 mutations and HER2 amplification (37:24) Experiences with surgery after neoadjuvant systemic therapy in NSCLC (55:38) Case: A woman in her mid-70s with localized pulmonary adenocarcinoma with a MET exon 14 skipping mutation (1:06:23) Clinical outcomes from the Phase III CheckMate 816 trial assessing nivolumab in combination with chemotherapy as neoadjuvant therapy for Stage IB-IIIA NSCLC (1:21:36) Case: A 48-year-old man with a 3.1-cm, Stage IB NSCLC with an EGFR exon 19 deletion (1:35:20) Management of oligometastatic disease with surgery and radiation therapy (1:43:32) Numeracy in adjuvant therapy for NSCLC; estimating the benefit to aid patients in therapeutic decision-making (1:49:11) CME information and select publications

Featuring an interview with Dr Ruben Mesa, including the following topics: Management of myeloproliferative neoplasms (MPNs) (0:00) Case: A man in his early 40s with MPN with a JAK2 mutation (27:17) Case: A man in his mid-50s with disease exacerbation 14 years after diagnosis of polycythemia vera (PV) (28:24) Case: A man in his mid-70s with post-PV myelofibrosis and resistance to ruxolitinib (30:50) CME information and select publications

Featuring perspectives from Dr Sara Tolaney, including the following topics: Introduction: DESTINY-Breast03 (0:00) Case: A woman in her early 50s with ER/PR-negative, HER2-positive breast cancer with bone, lung, liver and brain metastases — Justin Peter Favaro, MD, PhD (14:02) Case: A woman in her mid-70s with ER-positive, PR-negative, HER2-positive metastatic breast cancer — Sulfi Ibrahim, MD (18:38) Case: A woman in her early 60s with a localized 3.5-cm weakly ER/PR-positive, HER2-positive, node-negative breast cancer — Andrea Stebel, MD (28:18) Case: A woman in her early 40s with localized ER-negative, HER2-positive breast cancer — Ann Partridge, MD, MPH (31:04) Case: A woman in her early 40s with localized ER-positive, HER2-positive breast cancer — Kelly Yap, MD (36:26) Case: A woman in her late 30s with ER/PR-positive, HER2-positive, node-positive inflammatory breast cancer — Benjamin Parsons, DO (46:29) CME information and select publications

Featuring perspectives from Dr Loretta Nastoupil, including the following topics: Introduction (0:00) Case: A man in his late 60s with recurrent diffuse large B-cell lymphoma and disease progression after autologous stem cell transplant (8:29) Case: A man in his early 30s with classic nodular sclerosing Hodgkin lymphoma (22:46) Case: A man in his early 70s with follicular lymphoma who experiences disease relapse 1 year after completing lenalidomide/rituximab (27:25) Case: A man in his late 50s with relapsed mantle cell lymphoma after chimeric antigen receptor T-cell therapy (44:44) CME information and select publications

Featuring perspectives from Dr Jonathan Rosenberg, including the following topics: Introduction: Antibody-drug conjugates in the news (0:00) Case: A man in his early 70s with metastatic urothelial bladder cancer (mUBC) — Helen H Moon, MD (9:19) Case: A woman in her mid 80s with non-muscle-invasive UBC with an FGFR2 tumor mutation — Henna Malik, MD (15:14) Case: A woman in her early 70s with mUBC, PD-L1 30% — Sulfi Ibrahim, MD (27:46) Case: A woman in her mid-70s with BCG-refractory non-muscle-invasive bladder carcinoma in situ — Jason Hafron, MD (48:23) Case: A man in his early 60s with BCG-refractory non-muscle-invasive UBC — Dr Ibrahim (52:49) CME information and select publications

Featuring an interview with Dr Michael Mauro, including the following topics: Management of chronic myeloid leukemia (CML) (0:00) Case: A woman in her early 40s who received imatinib for 20 years for chronic-phase (CP) CML (37:45) Case: A man in his mid-60s with CP CML and cardiovascular risk factors (39:01) Case: A man in his early 50s with intermediate-risk CP CML 5 years undetectable on asciminib (40:43) CME information and select publications  

Featuring perspectives from Drs Andrew Evens, Ian Flinn and Gilles Salles, including the following topics: Introduction (0:00) Follicular Lymphoma (FL) (1:40) Case: A man in his early 70s with relapsed/refractory (R/R) FL — Andrew M Evens, DO, MSc (6:47) Case: A woman in her late 60s with R/R FL and an EZH2 mutation — Ian W Flinn, MD, PhD (15:00) Mantle Cell Lymphoma (MCL) (21:40) Case: A man in his early 70s with MCL — Dr Flinn (28:51) Case: A woman in her late 60s with MCL who received a Bruton tyrosine kinase inhibitor and received chimeric antigen receptor (CAR) T-cell therapy — Dr Evens (33:18) Case: A man in his early 60s with R/R MCL — Dr Flinn (36:04) Diffuse Large B-Cell Lymphoma (DLBCL) (37:41) Case: A man in his early 80s with R/R DLBCL — Dr Flinn (43:53) Case: A woman in her late 70s with DLBCL — Gilles Salles, MD, PhD (46:46) Case: A man in his late 20s with R/R DLBCL treated with CAR T-cell therapy — Dr Salles (51:00) CME information and select publications

Featuring perspectives from Dr John Leonard and Ms Amy Goodrich, including the following topics: Introduction (0:00) Diffuse Large B-Cell Lymphoma (1:24) Case: A man in his late 20s with newly diagnosed Hodgkin lymphoma — Amy Goodrich, CRNP (23:50) Hodgkin Lymphoma (27:04) Follicular Lymphoma (37:25) Case: A woman in her early 50s with Stage IVB follicular lymphoma — Ms Goodrich (45:25) Mantle Cell Lymphoma (50:52) Case: A man in his late 50s with Stage IVB mantle cell lymphoma — Ms Goodrich (53:53) NCPD information and select publications

Featuring perspectives from Drs Jeff Sharman, Mitchell Smith and Philip Thompson, including the following topics: Treatment of CLL in 2021 Introduction (0:00) First-line therapy for a younger and fit patient with CLL (11:52) Case: A man in his mid-60s with IGHV-unmutated CLL — Mitchell R Smith, MD, PhD (16:20) Case: A man in his mid-30s with IGHV-unmutated CLL — Philip A Thompson, MD, BS (20:24) Case: A woman in her late 60s with IGHV-mutated, trisomy 12, TP53 wild-type CLL — Jeff Sharman, MD (25:11) First-line therapy for older and frail patients with CLL (26:55) Case: A man in his early 70s with IGHV-unmutated CLL — Dr Thompson (31:04) First-line therapy for patients with high-risk CLL (33:37) Choice of Bruton tyrosine kinase (BTK) inhibitor for the treatment of CLL (36:02) Prevention and management of COVID-19 in patients with CLL (43:21) Future Treatment of CLL Future role of BTK inhibitors combined with venetoclax in the management of CLL (48:33) Future role of pirtobrutinib (LOXO-305) in the management of CLL (52:22) Case: A woman in her late 60s with multiregimen-relapsed CLL — Dr Sharman (55:10) Case: A woman in her mid-50s with multiregimen-relapsed CLL — Dr Thompson (57:32) CME information and select publications

Featuring perspectives from Drs Muhamed Baljevic, Joseph Mikhael and Nina Shah, moderated by Dr Robert Orlowski: Introduction (0:00) Up-Front Management of Newly Diagnosed Multiple Myeloma — Robert Z Orlowski, MD, PhD Selection and Sequencing of Therapies for Patients with Relapsed/Refractory Multiple Myeloma — Joseph Mikhael, MD (32:36) CAR (Chimeric Antigen Receptor) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma — Nina Shah, MD (50:28) Novel Agents and Strategies Under Investigation in Multiple Myeloma — Muhamed Baljevic, MD (1:10:11) CME information and select publications

Featuring perspectives from Drs Courtney DiNardo, Daniel Pollyea, David Sallman and Eunice Wang, including the following topics: Introduction (0:00) Prologue: A Personal Reflection on Acute Myeloid Leukemia (AML) (1:01) Case: A woman in her mid-80s with newly diagnosed AML — Daniel A Pollyea, MD, MS (8:28) Up-Front Treatment of AML in Patients Who Are Not Eligible for Intensive Therapy (11:54) Case: A man in his early 70s with AML and a complex monosomal karyotype — Dr Pollyea (24:32) Management of AML with Targetable Mutations (33:14) Case: A woman in her late 70s with AML and a FLT3-ITD mutation — Courtney D DiNardo, MD, MSCE (40:04) Case: A man in his late 70s with AML and diploid cytogenetics — Dr DiNardo (48:41) Other Currently Available and Investigational Treatment Strategies for AML (51:57) Case: A man in his mid-60s with secondary AML and DNMT3A and FLT3-ITD mutations — Eunice S Wang, MD (54:50) Case: A woman in her late 50s with leukemia cutis — Dr Wang (1:06:25) Case: A woman in her late 60s with lower-risk myelodysplastic syndrome (MDS) — David Sallman, MD (1:09:20) Case: A man in his late 70s with high-risk MDS — Dr Sallman (1:15:37) Case: A man in his mid-80s with high-risk MDS — Dr Sallman (1:22:27) CME information and select publications

Featuring perspectives from Drs Leonard Gomella, Maha Hussain, A Oliver Sartor and Neal Shore, including the following topics: Nonmetastatic (M0) Castration-Resistant Prostate Cancer (CRPC) Introduction: Personalized Continuing Medical Education (0:00) Case: A man in his early 70s with M0 CRPC — Gordon A Brown, DO (9:48) Case: A man in his late 70s with M0 CRPC — Sulfi Ibrahim, MD (17:13) Case: A man in his mid-70s with M0 CRPC — Jason Hafron, MD (22:11) Metastatic Hormone-Sensitive Prostate Cancer Case: A man in his late 60s with metastatic hormone-sensitive prostate cancer — Dr Brown (38:40) PARP Inhibitors in the Management of Metastatic CRPC (mCRPC) Case: A man in his mid-50s with mCRPC and a BRCA2 mutation — Dr Brown (48:53) Case: A man in his mid-70s with mCRPC and a somatic BRCA2 homozygous deletion — Dr Hafron (1:13:08) Case: A man in his mid-70s with mCRPC and a BRCA2 mutation — Dr Ibrahim (1:18:36) CME information and select publications

Featuring perspectives from Drs Edward Garon, Jarushka Naidoo, Harvey Pass and Heather Wakelee, including the following topics: Immunotherapy in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC) Introduction: Tumor board discussions since ASCO 2021 (0:00) Case: A woman in her early 60s with Stage IIA lung adenocarcinoma — PD-L1-negative, pan-wild type (8:00) Case: A man in his mid-50s with Stage IIA squamous NSCLC — PD-L1 15% (22:44) Case: A man in his early 90s with Stage IB lung adenocarcinoma — PD-L1 10% (31:47) Key relevant data sets (39:07) Adjuvant Treatment of NSCLC with a Driver Mutation Case: A man in his late 60s with Stage III lung adenocarcinoma — PD-L1

Featuring perspectives from Dr Carey Anders and Ms Jamie Carroll, including the following topics: Introduction (0:00) Prologue: The Summer of 2021 — Immunotherapy and PARP inhibitors enter the adjuvant/neoadjuvant settings (4:05) Case 1: A woman in her early 60s with ER/PR-positive, HER2-positive metastatic breast cancer — Jamie Carroll, APRN, MSN, CNP (17:19) Case 2: A woman in her late 30s with ER/PR-positive, HER2-negative, node-positive localized breast cancer — Ms Carroll (37:23) NCPD information and select publications

Featuring perspectives from Dr Thomas Herzog and Ms Kimberly Spickes, including the following topics: Ovarian Cancer with BRCA Mutations Introduction (0:00) Case: A woman in her early 50s with Stage IIIA2 ovarian cancer and a somatic BRCA2 mutation (11:01) Case: A woman in her late 50s with ovarian cancer and a germline BRCA1 mutation (35:03) Endometrial Cancer with Microsatellite Instability (MSI) or Stability Case: A woman in her late 60s with recurrent endometrial cancer, MSI high (36:35) Case: A woman in her mid-60s with recurrent endometrial cancer (43:22) Targeted Therapies for Relapsed Cervical Cancer Case: A woman in her mid-40s with recurrent cervical cancer, PD-L1 CPS 10 (53:13) NCPD information and select publications

Featuring perspectives from Drs Krishna Gundabolu, Richard M Stone and Eunice S Wang, moderated by Dr Harry Paul Erba, including the following topics:   Introduction (00:00) Case: A man in his late 60s with acute myeloid leukemia (AML) and an IDH2 mutation — Wendy Stock, MD (01:13) Case: A man in his early 80s with AML and multiple comorbidities who receives up-front venetoclax and azacitidine — Mark Levis, MD, PhD (06:00) Management of newly diagnosed AML in patients ineligible for intensive induction therapy (12:22) Case: A man in his early 70s with newly diagnosed AML with poor prognostic features — Dr Levis (21:36) Case: A woman in her late teens with AML and complex cytogenetics — Dr Stock (25:56) Treatment of AML in adult patients eligible for intensive therapy (30:48) Case: A man in his late 40s with newly diagnosed AML with poor prognostic features — Dr Levis (43:06) Case: A man in his late 70s with AML and FLT3 and IDH2 mutations — Dr Stock (46:24) Clinical decision-making for patients diagnosed with AML and an actionable mutation (54:27) Case: A man in his late 60s with transfusion-dependent myelodysplastic syndrome with ringed sideroblasts — Dr Stock (01:05:24) Current and future treatment considerations for patients with myelodysplastic syndromes (01:11:33)   CME information and select publications

Featuring an interview with Dr Sumanta Pal, including the following topics: First-Line Management of Advanced Renal Cell Carcinoma (RCC) (0:00) Case: A man in his early 70s with recurrent papillary RCC (23:31) Case: A man in his late 60s with metastatic RCC treated with first-line cabozantinib/nivolumab (26:22) Case: A man in his mid-50s with de novo metastatic RCC (28:14) CME information and select publications

Featuring slide presentations and related discussion from Dr Scott Kopetz. CME information and select publications

Featuring perspectives from Dr Scott Kopetz on cases from the practice of Dr Wells Messersmith, including the following topics: Ovarian Cancer with BRCA Mutations Introduction (0:00) Case: A woman in her early 50s with Stage IIIA2 ovarian cancer and a somatic BRCA2 mutation (11:01) Case: A woman in her late 50s with ovarian cancer and a germline BRCA1 mutation (35:03) Endometrial Cancer with Microsatellite Instability (MSI) or Stability Case: A woman in her late 60s with recurrent endometrial cancer, MSI high (36:35) Case: A woman in her mid-60s with recurrent endometrial cancer (43:22) Targeted Therapies for Relapsed Cervical Cancer Case: A woman in her mid-40s with recurrent cervical cancer, PD-L1 CPS 10 (53:13) CME information and select publications